Get the Daily Brief
Latest Biotech News
Wugen Raises $115 Million to Advance Off-the-Shelf CAR-T Therapy
Wugen Inc., focused on developing allogeneic CAR-T cell therapies, secured a $115 million financing led by Fidelity Management & Research to advance its lead candidate, WU-CART-007, targeting...
Massachusetts Biotech Funding Declines Amid Federal Policy Shifts
MassBio’s annual report reveals a significant downturn in Massachusetts-based biotech funding, with a more than 17% drop in venture capital investments to $2.75 billion in H1 2025, the lowest...
Tempus AI Expands Cancer Diagnostics Portfolio with Paige Acquisition
Tempus AI expanded its cancer diagnostics capabilities by acquiring digital pathology firm Paige for $81.3 million primarily in stock, bolstering its cancer diagnostics and research platforms with...
European Commission Approves ExCellThera’s Cord Blood Cell Therapy
The European Commission granted conditional marketing authorization to ExCellThera’s Zemcelpro, a cord blood-derived cell therapy designed for blood cancer patients lacking matched donors....
BindCraft AI Facilitates One-Shot Design of Functional Protein Binders
Researchers have introduced BindCraft, an artificial intelligence-driven pipeline that enables de novo design of specific protein binders with 10–100% success rates without requiring extensive...
FDA Narrows Approval of Updated COVID-19 Boosters to High-Risk Adults
The US FDA approved updated COVID-19 booster vaccines from Pfizer, Moderna, and Novavax that target currently circulating coronavirus strains but limited usage to adults aged 65 and older or those...
Akeso’s PD-1/VEGF Bispecific Antibody Shows Survival Benefit in Lung Cancer
Data from a China-based study indicate that Akeso Pharmaceuticals’ bispecific antibody ivonescimab targeting PD-1 and VEGF achieved a statistically significant overall survival benefit when...
FDA Narrows Scope of Updated COVID-19 Boosters Amid Rising Cases
The U.S. Food and Drug Administration has approved updated COVID-19 vaccines targeting a prevalent coronavirus strain, but restricted their use primarily to adults 65 and older and high-risk...
Eli Lilly’s Oral GLP-1 Orforglipron Shows Weight and Blood Sugar Reductions
Eli Lilly’s investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, demonstrated significant efficacy in a late-stage Phase III trial for adults with obesity and type...
Regeneron’s Cemdisiran Meets Phase III Endpoints in Myasthenia Gravis
Regeneron Pharmaceuticals, licensing cemdisiran from Alnylam Pharmaceuticals, reported successful Phase III results in generalized myasthenia gravis, an autoimmune neuromuscular disease. The siRNA...
AbbVie Acquires Gilgamesh’s Psychedelic Candidate for Depression in $1.2B Deal
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals' lead investigational drug, bretisilocin, a psychedelic compound in Phase II development for major depressive disorder. Bretisilocin is...
Groundbreaking AI Model BindCraft Boosts Functional Protein Design Success Rates
Researchers at École Polytechnique Fédérale de Lausanne have developed BindCraft, an advanced deep learning framework that significantly improves the success rate of functional protein binder...
New Research Foundation Launches with $500 Million for Transformative Science
The Fund for Science and Technology (FFST), funded by Paul G. Allen's estate, announced a $500 million commitment over four years to support ambitious scientific and technological research...
Structural Breakthroughs Reveal Human Cannabinoid Receptor CB1 Activation
Scientists have unveiled high-resolution crystal structures of the human cannabinoid receptor CB1 bound to two distinct agonists. This advancement elucidates the receptor's activation mechanisms,...
Wugen Raises $115 Million to Advance Off-the-Shelf CAR-T Therapy for T-Cell Malignancies
Cell therapy biotech Wugen secured $115 million in financing led by Fidelity Management to advance WU-CART-007, an allogeneic 'off-the-shelf' CAR-T treatment targeting relapsed or refractory...
Light-Activated Pills Unlock New Insights into Gut-Brain Communication
Researchers have developed innovative light-activated pills that enable noninvasive exploration of the gut's complex nervous system, often referred to as the body's 'second brain.' This technology...
European Commission Approves First Cord Blood-Derived Cell Therapy for Blood Cancer Patients
The European Commission has granted conditional marketing authorization to Zemcelpro, developed by ExCellThera, the first cell therapy in Europe designed for blood cancer patients lacking matched...
FDA narrows updated Covid boosters to high-risk groups
The FDA approved updated Covid-19 vaccines from Pfizer, Moderna, and Novavax targeting the LP.8.1 subvariant for the 2025-26 season but limited their use to individuals at higher risk due to...
AbbVie acquires Gilgamesh’s psychedelic depression drug
AbbVie announced a deal valued up to $1.2 billion to acquire Gilgamesh Pharmaceuticals’ lead psychedelic candidate, bretisilocin, designed for major depressive disorder (MDD). Bretisilocin, a...
Lilly’s oral GLP-1 shows weight loss, diabetes benefits; regulatory filing pending
Eli Lilly announced positive Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist, demonstrating significant weight loss and glycemic control improvements in adults with obesity...